Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 385

1.

Biosimilars 101: considerations for U.S. oncologists in clinical practice.

Camacho LH, Frost CP, Abella E, Morrow PK, Whittaker S.

Cancer Med. 2014 Aug;3(4):889-99. doi: 10.1002/cam4.258. Epub 2014 May 9. Review.

2.

Biosimilar safety considerations in clinical practice.

Choy E, Jacobs IA.

Semin Oncol. 2014 Feb;41 Suppl 1:S3-14. doi: 10.1053/j.seminoncol.2013.12.001. Epub 2013 Dec 6.

PMID:
24560025
3.

Similar names for similar biologics.

Casadevall N, Felix T, Strober BE, Warnock DG.

BioDrugs. 2014 Oct;28(5):439-44. doi: 10.1007/s40259-014-0099-9.

PMID:
25001080
4.

Developing clinical trials for biosimilars.

Bui LA, Taylor C.

Semin Oncol. 2014 Feb;41 Suppl 1:S15-25. doi: 10.1053/j.seminoncol.2013.12.002. Epub 2013 Dec 7. Review.

PMID:
24560024
5.

Biosimilars: A consideration of the regulations in the United States and European union.

Daller J.

Regul Toxicol Pharmacol. 2016 Apr;76:199-208. doi: 10.1016/j.yrtph.2015.12.013. Epub 2015 Dec 28.

PMID:
26732800
6.

Biosimilars in oncology: from development to clinical practice.

Rak Tkaczuk KH, Jacobs IA.

Semin Oncol. 2014 Apr;41 Suppl 3:S3-S12. doi: 10.1053/j.seminoncol.2014.03.008. Epub 2014 Mar 13. Review.

7.

Pharmacist Substitution of Biological Products: Issues and Considerations.

Li E, Ramanan S, Green L.

J Manag Care Spec Pharm. 2015 Jul;21(7):532-9.

8.

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM.

J Natl Compr Canc Netw. 2011 Sep;9 Suppl 4:S1-22.

PMID:
21976013
9.

Biosimilars: Practical Considerations for Pharmacists.

Stevenson JG, Popovian R, Jacobs I, Hurst S, Shane LG.

Ann Pharmacother. 2017 Jul;51(7):590-602. doi: 10.1177/1060028017690743. Epub 2017 Feb 8. Review.

PMID:
28176529
10.

Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.

Grabowski HG, Guha R, Salgado M.

Health Aff (Millwood). 2014 Jun;33(6):1048-57. doi: 10.1377/hlthaff.2013.0862.

PMID:
24889955
11.

Pharmacovigilance and biosimilars: considerations, needs and challenges.

Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG.

Expert Opin Biol Ther. 2013 Jul;13(7):1039-47. doi: 10.1517/14712598.2013.783560. Epub 2013 Mar 26. Review.

PMID:
23527621
12.

Biosimilars: Implications for health-system pharmacists.

Lucio SD, Stevenson JG, Hoffman JM.

Am J Health Syst Pharm. 2013 Nov 15;70(22):2004-17. doi: 10.2146/ajhp130119.

13.

Biosimilar safety factors in clinical practice.

Reinisch W, Smolen J.

Semin Arthritis Rheum. 2015 Jun;44(6 Suppl):S9-15. doi: 10.1016/j.semarthrit.2015.04.005.

14.

Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.

Ahmed I, Kaspar B, Sharma U.

Clin Ther. 2012 Feb;34(2):400-19. doi: 10.1016/j.clinthera.2011.12.005. Epub 2012 Jan 13. Review.

PMID:
22244050
15.

Biosimilars: Here and Now.

Lemery SJ, Esteva FJ, Weise M.

Am Soc Clin Oncol Educ Book. 2016;35:e151-7. doi: 10.14694/EDBK_155954.

16.

Biosimilars in inflammatory bowel disease.

Gargallo CJ, Lué A, Gomollón F.

Minerva Med. 2017 Jun;108(3):239-254. doi: 10.23736/S0026-4806.17.05050-9. Epub 2017 Feb 7. Review.

PMID:
28176515
17.

The challenge of indication extrapolation for infliximab biosimilars.

Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, Zou G, Xu Z, Shankar G, Sealey DC, Russell AS.

Biologicals. 2014 Jul;42(4):177-83. doi: 10.1016/j.biologicals.2014.05.005. Epub 2014 Jun 21. Review.

18.

Development of biosimilars in an era of oncologic drug shortages.

Li E, Subramanian J, Anderson S, Thomas D, McKinley J, Jacobs IA.

Drug Des Devel Ther. 2015 Jun 24;9:3247-55. doi: 10.2147/DDDT.S75219. eCollection 2015. Review.

19.

Developing oncology biosimilars: an essential approach for the future.

Abraham J.

Semin Oncol. 2013 Dec;40 Suppl 1:S5-24. doi: 10.1053/j.seminoncol.2013.09.015. Review.

PMID:
24267944
20.

Biosimilars: are they ready for primetime in the United States?

Hirsch BR, Lyman GH.

J Natl Compr Canc Netw. 2011 Aug 1;9(8):934-42; quiz 943.

PMID:
21900222

Supplemental Content

Support Center